Search research articles
Contact Us
Filters
Showing results (331-340 of 348) with videos related to
Page
of 35
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
March 12, 2022
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
Martin J Edelman, Mikhail Dvorkin, Konstatin Laktionov, et al.
Journal of the National Cancer Institute
|
March 19, 2013
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy
Steven H Lin, Thomas J George, Edgar Ben-Josef, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 25, 2009
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer
Lecia V Sequist, Panos M Fidias, Jennifer S Temel, et al.
JCO Precision Oncology
|
September 7, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)
Riha Vaidya, Joseph M Unger, Lu Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 2025
Safety and Tolerability of Lete-cel in NSCLC-Reply
Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2024
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer
Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
The Journal of Biological Chemistry
|
January 28, 2015
Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer
Fernanda I Staquicini, Ming D Qian, Ahmad Salameh, et al.
Cancer Discovery
|
October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Investigational New Drugs
|
January 25, 2024
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Oluwadunni E Emiloju, Jun Yin, Emily Koubek, et al.
Journal for Immunotherapy of Cancer
|
January 28, 2022
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10<sup>+</sup> advanced non-small cell lung cancer
George R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, et al.
Page
of 35
Search research articles
Search
Showing results (331-340 of 348) with videos related to
Sort By:
Page
of 35
Lung Cancer (Amsterdam, Netherlands)
|
March 12, 2022
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
Martin J Edelman, Mikhail Dvorkin, Konstatin Laktionov, et al.
Journal of the National Cancer Institute
|
March 19, 2013
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy
Steven H Lin, Thomas J George, Edgar Ben-Josef, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 25, 2009
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer
Lecia V Sequist, Panos M Fidias, Jennifer S Temel, et al.
JCO Precision Oncology
|
September 7, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)
Riha Vaidya, Joseph M Unger, Lu Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 2025
Safety and Tolerability of Lete-cel in NSCLC-Reply
Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2024
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer
Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
The Journal of Biological Chemistry
|
January 28, 2015
Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer
Fernanda I Staquicini, Ming D Qian, Ahmad Salameh, et al.
Cancer Discovery
|
October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Investigational New Drugs
|
January 25, 2024
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Oluwadunni E Emiloju, Jun Yin, Emily Koubek, et al.
Journal for Immunotherapy of Cancer
|
January 28, 2022
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10<sup>+</sup> advanced non-small cell lung cancer
George R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, et al.
Page
of 35